Avoidance of Calcineurin Inhibitors With Use of Proliferation Signal Inhibitors in De Novo Heart Transplantation With Renal Failure

Journal of Heart and Lung Transplantation

Volumn 27, Issue 10, 2008, Pages 1135-1141

  González Vílchez, Francisco ^a   Vázquez de Prada, José Antonio ^a   Exṕosito, Víctor ^a   García Camarero, Tamara ^a   Fernández Friera, Leticia ^a   Llano, Miguel ^a   Ruano, Javier ^a   Martín Durán, Rafael ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; ASTHENIA; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIALYSIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART GRAFT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODIAFILTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; PLEURA EFFUSION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; THORACOCENTESIS; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AZATHIOPRINE; CALCINEURIN; CELL DIVISION; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 53049096567     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.07.020     Document Type: Article

References (23)

1. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
2. Viganò M., Tuzcu M., Benza R., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 26 (2007) 584-592
3. Raichlin E., Bae J.H., Khalpey Z., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116 (2007) 2726-2733
4. Valantine H. Is There a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation?. Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 26 (2007) 557-564
5. Kushwaha S.S., Khalpey Z., Frantz R.P., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24 (2005) 2129-2136
6. Rothenburger M., Teerling E., Bruch C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 26 (2007) 250-257
7. Hunt J., Lerman M., Magee M.J., et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 24 (2005) 1863-1867
8. Gustafsson F., Ross H.J., Delgado M.S., et al. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 26 (2007) 998-1003
9. Balfour I.C., Srun S.W., and Wood E.G. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant (2006) 518-522
10. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with MMF (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
11. Lehmkuhl H.B., Mai D., Dandel M., et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 26 (2007) 700-704
12. Meiser B., Kaczmarek I., Mueller M., et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 26 (2007) 598-603
13. Meiser B., Reichart B., Adamidis I., Überfuhr P., and Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5 (2005) 827-831
14. Fernández-Valls M., González-Vílchez F., Vazquez de Prada J.A., Ruano J., and Martin Durán R. Use of sirolimus as an alternative to anticalcineurinic therapy in heart transplantation. Experience of a single center. Transplant Proc 37 (2005) 4012-4023
15. Vazquez de Prada J.A., González Vílchez F., Cobo M., et al. Sirolimus in de novo heart transplant recipients with severe renal impairment. Transpl Int 19 (2006) 245-248
16. Vazquez de Prada J.A. A critical review of the role of endomyocardial biopsy in heart transplantation]. Rev Esp Cardiol 48 suppl 7 (1995) 86-91
17. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
18. Odim J., Wheat J., Laks H., et al. Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 162-166
19. Delgado D.H., Miriuka S.G., Cusimano R.J., Feindel C., Rao V., and Rossa H.J. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 24 (2005) 166-169
20. Hunt J., Bedanova H., Starling R.C., et al. Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 26 suppl 2 (2007) 398
21. Delgado J.F., Torres J., Ruiz-Cano M.J., et al. Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 25 (2006) 1171-1174
22. Dodd D.A., and Burger J. Use of endomyocardial biopsy for rejection surveillance in pediatric heart transplant patients. J Heart Lung Transplant 26 (2007) S245-S246
23. Dandel M., Hummel M., Muller J., et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 104 suppl I (2001) I-184-I-191